Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Schellong

Showing results (51-60 of 117) with videos related to

Pageof 12
Sort By:
The New England Journal of Medicine|February 22, 2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolismSam Schulman, Clive Kearon, Ajay K Kakkar, et al.
Thrombosis and Haemostasis|September 26, 2015
Bleeding events with dabigatran or warfarin in patients with venous thromboembolismAmmar Majeed, Samuel Z Goldhaber, Ajay Kakkar, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|September 12, 2022
GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwideSylvia Haas, John A Camm, Darius Harald, et al.
Thrombosis and Haemostasis|December 30, 2020
Prognostic Impact of Obstructive Sleep Apnea in Patients Presenting with Acute Symptomatic Pulmonary EmbolismRaphael Le Mao, David Jiménez, Behnood Bikdeli, et al.
Archivos De Bronconeumologia|July 16, 2023
Identification of Low-risk Patients With Acute Symptomatic Pulmonary EmbolismDavid Jiménez, Behnood Bikdeli, Carmen Rodríguez, et al.
Blood|July 16, 2008
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging StudyHarry R Buller, Anthonie W A Lensing, Martin H Prins, et al.
Journal of Thrombosis and Thrombolysis|March 2, 2011
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocolAlexander Thomas Cohen, Theodore Erich Spiro, Harry Roger Büller, et al.
European Journal of Internal Medicine|November 18, 2022
Deep vein thrombosis symptoms and 30-day mortality in acute pulmonary embolismÁlvaro Dubois-Silva, Cristina Barbagelata-López, Patricia Piñeiro-Parga, et al.
Seminars in Thrombosis and Hemostasis|May 10, 2021
Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE StudySebastian Schellong, Walter Ageno, Ivan B Casella, et al.
Blood|December 8, 2009
The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopeniaNorbert Lubenow, Peter Hinz, Simone Thomaschewski, et al.
Pageof 12

Showing results (51-60 of 117) with videos related to

Sort By:
Pageof 12
The New England Journal of Medicine|February 22, 2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolismSam Schulman, Clive Kearon, Ajay K Kakkar, et al.
Thrombosis and Haemostasis|September 26, 2015
Bleeding events with dabigatran or warfarin in patients with venous thromboembolismAmmar Majeed, Samuel Z Goldhaber, Ajay Kakkar, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|September 12, 2022
GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwideSylvia Haas, John A Camm, Darius Harald, et al.
Thrombosis and Haemostasis|December 30, 2020
Prognostic Impact of Obstructive Sleep Apnea in Patients Presenting with Acute Symptomatic Pulmonary EmbolismRaphael Le Mao, David Jiménez, Behnood Bikdeli, et al.
Archivos De Bronconeumologia|July 16, 2023
Identification of Low-risk Patients With Acute Symptomatic Pulmonary EmbolismDavid Jiménez, Behnood Bikdeli, Carmen Rodríguez, et al.
Blood|July 16, 2008
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging StudyHarry R Buller, Anthonie W A Lensing, Martin H Prins, et al.
Journal of Thrombosis and Thrombolysis|March 2, 2011
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocolAlexander Thomas Cohen, Theodore Erich Spiro, Harry Roger Büller, et al.
European Journal of Internal Medicine|November 18, 2022
Deep vein thrombosis symptoms and 30-day mortality in acute pulmonary embolismÁlvaro Dubois-Silva, Cristina Barbagelata-López, Patricia Piñeiro-Parga, et al.
Seminars in Thrombosis and Hemostasis|May 10, 2021
Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE StudySebastian Schellong, Walter Ageno, Ivan B Casella, et al.
Blood|December 8, 2009
The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopeniaNorbert Lubenow, Peter Hinz, Simone Thomaschewski, et al.
Pageof 12